THE GRAND CORPORATIONS Party (GOP), which is more pro-corporations than the Democrats, would have us believe that it will make the patent system better. Well, better for who exactly? Large corporations? It's obvious that patent trolls harm large corporations, but what about the interests of individual people and what about massive corporations that are patent parasites? We have written so much about this subject for years and we nearly got sick of it when the corporate press only ever spoke about patent trolls as the issue but never about patent scope.
Yesterday afternoon, the twitter feed for "LillyPad," which is Eli Lilly's "policy" blog and Twitter feed, excitedly tweeted out a quote from Stefan Oschmann, an executive at pharmaceutical competitor Merck, who was just elected as the new head of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) -- basically, the big pro-pharma lobbying group. The tweet is no longer there, because LillyPad deleted it, but here's a screenshot I took apparently seconds before it disappeared...
[...]
But it appears that Eli Lilly (and IFPMA) have no interest in being intellectually honest or having such a discussion. No, they've decided to stick to the ridiculous and bogus corporate line that patents are all butterflies and roses, and do no harm at all. What a wasted opportunity -- even if it helped show the true colors of the current leadership of the pharmaceutical industry.
A Republican takeover of the U.S. Senate has brightened prospects for an effort to fight frivolous patent litigation, although the path to success is far from clear, sources close to the lobbying effort said on Wednesday.
The House of Representatives easily passed a bill in December to cut down on abusive litigation brought by patent assertion entities, or "patent trolls": companies that buy or license patents, then aggressively pursue licensing fees or file infringement lawsuits.
That legislation, backed by technology companies like Cisco Systems Inc and Google Inc, stalled in the Senate amid opposition from drug companies and, crucially, lack of backing from Democratic Senate Majority Leader Harry Reid.
A centerpiece of the effort was a provision that encouraged judges hearing patent cases to award fees to the winners of infringement lawsuits.
On the plus side for tech, with the GOP taking over the U.S. Senate, patent reform efforts received new life, as Mike Allen of Politico noted this morning.